iBio Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Annual report [Section 13 and 15(d), not S-K Item 405]

Significant Transactions (Details)

Significant Transactions (Details)									3 Months Ended	12 Months Ended
Significant Transactions (Details)	Apr. 21, 2025 USD ($)	Jan. 29, 2025 USD ($) shares	Jan. 28, 2025 USD ($) shares	Feb. 25, 2024 USD ($)	Dec. 01, 2022	Sep. 16, 2022 USD ($) shares	Nov. 01, 2021 USD ($) $ / shares shares	Aug. 23, 2021 USD ($) shares	Dec. 31, 2022 USD ($)	Jun. 30, 2025 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2022 USD ($)	Sep. 16, 2022	Sep. 16, 2022 lease
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from sale of intellectual property											$ 1,000,000
Accrued licensing fee payable										$ 1,345,000	2,028,000
General and administrative expenses										10,690,000	11,674,000
Intellectual Property
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Indefinite-lived intangible assets										5,003,000	5,003,000
RubrYc Therapeutics
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of equipment leases assumed in asset acquisition													3
PD-1 Asset Purchase Agreement \| Otsuka Pharmaceutical \| Intellectual Property
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from sale of intellectual property				$ 1,000,000
Potential contingent payments related to sale of intellectual property				$ 52,500,000
The Purchase and Sale Agreement \| College Station Investors
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Purchase price for Ground Lease Property							$ 28,750,000
Proceeds from sale of building							28,000,000
Base rent expense							$ 151,450
Interest rate on lease (percentage of facility's market value)							6.50%
The Credit Agreement \| Woodforest National Bank
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Principal amount borrowed							$ 22,375,000
The Warrant \| Bryan Capital \| iBio Common Stock
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Warrants, shares issued \| shares							2,579
Exercise price per share of warrants \| $ / shares							$ 665
Warrants issued and exercisable \| shares							579
Value of exercisable warrants							$ 217,255
Collaboration, Option and License Agreement \| RubrYc Therapeutics
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration and license agreement, agreement term								5 years
AstralBio Exclusive License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payment of upfront licensing fee		$ 750,000
Number of shares issued per agreement \| shares		246,087
Activin E License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payment of upfront licensing fee	$ 750,000
Aggregate potential milestone payments payable in licensing agreement	$ 28,000,000
Equity ownership (ceiling)	19.90%
Notice period to cancel licensing agreement	45 days
Notice period to cancel licensing agreement (material breach of contract)	90 days
Indefinite-lived intangible assets	$ 750,000
Myostatin License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payment of upfront licensing fee			$ 750,000
Potential contingent payments related to sale of intellectual property			$ 28,000,000
Equity ownership (ceiling)			19.90%
Notice period to cancel licensing agreement			45 days
Notice period to cancel licensing agreement (material breach of contract)			90 days
Number of shares issued per agreement \| shares			246,087
Stock Purchase Agreement \| RubrYc Therapeutics \| Series A-2 Preferred Stock
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Shares purchased in transaction \| shares								2,864,345
Value of shares purchased in transaction								$ 7,500,000
Asset Purchase Agreement \| RubrYc Therapeutics
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Liability for contingent consideration						$ 5,000,000
Cash advances to RubrYc to support operations						484,000
Transaction costs						208,000
Impairment of investment in RubrYc												$ 1,760,000
Impairment of current prepaid expense												288,000
Impairment of noncurrent prepaid expense												$ 864,000
Number of equipment leases assumed in asset acquisition													3	3
Financing lease liabilities assumed in acquisition						$ 814,000
Asset Purchase Agreement \| RubrYc Therapeutics \| iBio Common Stock
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares issued per agreement \| shares						5,117
Fair value of shares issued in agreement						$ 1,000,000
Fair value of shares issued and subject to lockup period						$ 650,000
Separation Agreement and General Release \| Mr. Thomas F. Isett, Former Chief Executive Officer
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Period of bi-monthly installments of current base salary					24 months
Period of bi-monthly installments of target bonus					24 months
General and administrative expenses									$ 2,130,000
Accrued expenses										$ 0	$ 500,000